Postintervention Interleukin‐6 (IL‐6) Level, Rather than the Pretreatment or Dynamic Changes of IL‐6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

Conclusion.Our study suggests that the post‐treatment serum IL‐6 level, rather than pretreatment or dynamic changes of IL‐6, serves as a powerful predictor for tumor response. These findings provide evidence to help discriminate between patients who will particularly benefit from TACE and those who require more personalized therapeutic regimens and rigorous surveillance.Implications for Practice.Transarterial chemoembolization (TACE) is a major therapeutic regimen for advanced hepatocellular carcinoma. Thus, identification of early practical markers of tumor response to TACE is of high importance. This study indicated that the post‐treatment serum interleukin‐6 (IL‐6) level, rather than the pretreatment or dynamic changes of IL‐6, serves as a powerful predictor for tumor response. A combined index based on the post‐TACE IL‐6 level and post‐/pre‐TACE neutrophils ratio is optimal for predetermining an objective response after TACE, which may be helpful in guiding individualized treatments and surveillance.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Hepatobiliary, Radiation Oncology, Cancer Diagnostics and Molecular Pathology Source Type: research